AstraZeneca Investor Event Presentation Deck
September 2024, 55 slides
  1. AstraZeneca
  2. Related Decks
  3. Investor Event Presentation Decks
meet management and manager | AstraZeneca
forward looking statements | AstraZeneca
and | AstraZeneca
and | AstraZeneca
furthering our oncology ambition | AstraZeneca
ambition total revenue by sustained growth | AstraZeneca
investing in disruptive categories to drive growth | AstraZeneca
ambition in oncology opt | AstraZeneca
positive oncology since beginning of | AstraZeneca
presence at and a a | AstraZeneca
| AstraZeneca
and data mark key steps in delivering oncology ambition | AstraZeneca
patient selection | AstraZeneca
why is different from other | AstraZeneca
novel solution for | AstraZeneca
what is quantitative continuous scoring | AstraZeneca
cut points were for in lung non aga patients | AstraZeneca
status was predictive of efficacy in lung | AstraZeneca
five trials ongoing representing significant share of potential pyr pyr | AstraZeneca
potential real world implementation of follows same path as other companion diagnostics | AstraZeneca
| AstraZeneca
high unmet need remains in muscle invasive bladder cancer | AstraZeneca
is phase trial of patients with eligible who were planned for radical cystectomy eke | AstraZeneca
was designed with a multiple testing procedure across key primary and secondary | AstraZeneca
characteristics were generally well balanced | AstraZeneca
regimen improved event free survival comparator arm | AstraZeneca
consistent benefit for across key subgroups | AstraZeneca
demonstrated improvement in overall survival with arm | AstraZeneca
consistent benefit across subgroups | AstraZeneca
regimen generally well tolerated | AstraZeneca
common aes in line with known profile for the regimen | AstraZeneca
conclusions | AstraZeneca
in bladder cancer | AstraZeneca
establishes as a key player in bladder cancer | AstraZeneca
multiple reasons for confidence in success | AstraZeneca
a session i | AstraZeneca
driving the revolution a | AstraZeneca
expanding leadership position in growing market | AstraZeneca
designed to address unmet need across multiple types | AstraZeneca
profiles of and demonstrate stability of linker in platform and support dosing | AstraZeneca
promising efficacy in heavily treated patients with ovarian breast and endometrial cancer sie | AstraZeneca
differentiated efficacy in heavily patients with platinum resistant relapsed ovarian cancer | AstraZeneca
next generation | AstraZeneca
leading in next wave | AstraZeneca
encouraging preliminary response rates and durable responses in metastatic naive | AstraZeneca
differentiated safety profile enables combination in gastric and cancers | AstraZeneca
promising activity particularly in population a group with high unmet need | AstraZeneca
closing remarks | AstraZeneca
ambition in oncology | AstraZeneca
significant oncology news flow across key medicines through | AstraZeneca
a session | AstraZeneca
appendix | AstraZeneca
in lung cancer | AstraZeneca
in breast cancer | AstraZeneca
glossary | AstraZeneca
See More
AstraZeneca
Investor Event Presentation Decks
Drug Manufacturers—General Decks
Healthcare Decks
Explore Topics
Oncology
Cancer
Lung
Recent decks by AstraZeneca
Results
November 2024
Results
November 2024
Results
February 2024
Investor Conference
January 2024
See all presentations by AstraZeneca (30 decks)
Related decks
Genprex
Investor Presentation
October 2022
Genprex
Investor Presentation
October 2022
BioNTech
Results
May 2021
Nuvectis Pharma
Investor Presentation
July 2023
Genelux
Investor Presentation
December 2023
BioNTech
Results
March 2022
Exscientia
Results
November 2023
Genetron
Results
June 2022
Recent decks by AstraZeneca
See all presentations (30 decks)
Results
November 2024
Results
November 2024
Results
February 2024
Investor Conference
January 2024
Genprex
Investor Presentation
October 2022
Genprex
Investor Presentation
October 2022
BioNTech
Results
May 2021
Nuvectis Pharma
Investor Presentation
July 2023
Genelux
Investor Presentation
December 2023
BioNTech
Results
March 2022
Exscientia
Results
November 2023
Genetron
Results
June 2022
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights

Stay in the loop

Join our mailing list to stay in the loop with updates and newest feature releases

Presentations

Start Up
IPO
SPAC
M&A
Investor Day
Results
ESG
Credit
Investment Banking

Explore

Presentation Collections
Slide Collections

Company

Blog
Contact us
© 2021-2024 Slidebook.io